|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, these sustained response rates can be significantly increased by carefully selecting candidates for PEG-IFN therapy based upon baseline ALT and HBV DNA levels, viral genotype and IL28B polymorphisms, by extending PEG-IFN therapy beyond 48 weeks and, most importantly, by applying early on-treatment stopping rules based upon HBsAg kinetics.
|
23286860 |
2013 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured the frequencies of circulating myeloid (mDC) and plasmacytoid (pDC) dendritic cells and IFN-α production along with the expression of DC-SIGN and Toll Like Receptors (TLR's) in HBV patients at different time points.
|
27658394 |
2016 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found a significant (P < 0.01) correlation between the HBV DNA levels at midtreatment and response to IFN therapy.
|
9658370 |
1998 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Defining an "immediate virological response (IVR)" as the loss of serum hepatitis C virus (HCV) RNA 7 d after the first administration of PEG-IFN alpha, we conducted a 12-wk course of PEG-IFN alpha2a monotherapy without the addition of ribavirin for 38 patients who had low pretreatment HCV RNA load and exhibited IVR.
|
20333792 |
2010 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients.
|
30133478 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR.
|
27793564 |
2016 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-α in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-α against HBV.(Hepatology 2018;67:1237-1252).
|
29059468 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
|
28983111 |
2017 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-alpha2b plus ribavirin treatment.
|
17287904 |
2006 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα.
|
30723923 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment.
|
29791282 |
2018 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on these results, precore mutants do respond to IFN, and therefore, IFN is indicated in patients with HBeAb, especially those with low serum HBV DNA levels.
|
8745316 |
1995 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The biochemical and virological responses to combined PEG-IFN and RBV therapy might be similar in CHC patients with or without occult HBV infection.
|
19817959 |
2010 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification.
|
29079518 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL).
|
28635613 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).
|
15952104 |
2005 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicated that the expression of the innate immune factors MOV10, A3G, and IFN-α is affected by chronic HBV infection.
|
24871977 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study.
|
24517415 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hepatitis B serological markers and viral loads were tested every 3 months until 1 year after stopping Peg-IFN therapy.
|
25835020 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR.
|
31446638 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM.
|
29901821 |
2018 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection.
|
23907803 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The content of HBV DNA in the supernatant of co-cultivation of HepG2.2.15 cells and PBMCs without stimulated materials was higher than that stimulated by HBcAg and IL-18 at various concentrations of HBcAg and IL-18 together with IL-12/IFN-alpha 1b.
|
15138116 |
2004 |